- A Section 503B outsourcing facility compounds a batch of a sterile analgesic solution and ships it to a hospital pharmacy without a patient-specific prescription for each unit. Which of the following most accurately describes whether this is permissible?
Answer: This is permissible if the facility complies with cGMP, FDA registration, and reporting requirements.
Section 503B outsourcing facilities are specifically authorized to compound drug products and distribute them to healthcare providers including hospitals without patient-specific prescriptions. This is a core purpose of the 503B category, which was created to provide a pathway for anticipatory compounding for healthcare facilities while ensuring quality through cGMP and FDA oversight. A is incorrect because patient-specific prescriptions are a 503A requirement; the 503B framework was designed to operate without them. B is incorrect because sterile compounding may be performed by both 503A and 503B entities under applicable standards. D is incorrect because a shortage confirmation is not required before a 503B facility may provide products to a hospital; the 503B framework permits this activity generally.
- A 503A pharmacy that engages in anticipatory compounding must maintain records of anticipatory batches. Which of the following information is most critical to include in these records?
Answer: The formula and preparation method, quantity prepared, date of preparation, assigned BUD, raw material lot numbers, and compounder identification.
Records for anticipatory compounded preparations must include the formula and preparation method, quantity prepared, date of preparation from which the BUD is calculated, the assigned BUD, raw material lot numbers for traceability, and identification of the compounder. These elements are required under USP compounding standards and state board regulations for accountability and quality assurance. A is incorrect because patient contact information is not a required element of compounding batch records; patient records are separate from compounding records. C is incorrect because pricing and profit margin are not regulatory recordkeeping requirements. D is incorrect because state board written authorization for each batch is not a standard requirement for routine anticipatory compounding that falls within permitted limits.
- A physician requests that a 503A pharmacy compound a pain preparation for office use to administer to patients during office visits. State law permits limited office-use compounding under specific conditions. The FDA has indicated that office-use compounding without patient-specific prescriptions is generally inconsistent with 503A. Which of the following best analyzes the applicable legal framework?
Answer: State law allows limited office-use compounding, but pharmacies must consider FDA enforcement risks due to 503A restrictions on non-patient-specific prescriptions.
The legal analysis is genuinely complex. State pharmacy practice acts may authorize certain office-use compounding under specific conditions. However, the FDA has indicated that office-use compounding without patient-specific prescriptions is generally inconsistent with 503A, creating potential federal enforcement risk even when state law permits the activity. A is incorrect because pharmacy practice is not exclusively a state regulatory domain; the FDCA also applies. B is incorrect because the FDA's position does not automatically preempt all state office-use compounding authority; the interplay requires nuanced analysis. C is incorrect because the administration model does not automatically resolve the federal regulatory concern; the applicable frameworks address the conditions of compounding, not only how the compound is used.
- Under FDCA Section 503A, which of the following factors is most relevant in determining the permissible quantity of anticipatory compounding for a specific preparation?
Answer: The pharmacy's documented history of receiving and dispensing prescriptions for that particular preparation.
Under 503A, anticipatory compounding must be based on the pharmacy's documented history of receiving and filling prescriptions for the specific preparation. This historical data establishes what quantity is reasonably anticipated to be needed and defines the permissible scope of advance preparation. A is incorrect because raw material cost is not a regulatory factor in determining anticipatory compounding limits. B is incorrect because a prescriber's projected patient volume is not the standard; the pharmacy's own historical prescription data governs. C is incorrect because the FDA shortage list does not expand anticipatory compounding limits under 503A; it is relevant to enforcement discretion but does not redefine the quantity standard.
- A 503A traditional pharmacy has been compounding a specific pain cream for a long-standing group of patients. With no current patient-specific prescriptions on hand, the pharmacist wants to compound 500 units in advance to meet an anticipated busy month. Which of the following best applies?
Answer: The pharmacy may compound only a limited quantity anticipatorily based on its prescription history; compounding 500 units without patient-specific prescriptions may exceed permissible anticipatory limits and approach manufacturing.
Under FDCA Section 503A, anticipatory compounding is permitted only in limited quantities based on a documented history of compounding that particular preparation. Compounding 500 units in the absence of patient-specific prescriptions may significantly exceed the reasonable proportion of anticipatory to patient-specific compounding and could be characterized as manufacturing, which requires FDA approval. A is incorrect because 503A pharmacies do not have broad authority for unlimited anticipatory compounding. B is incorrect because prior compounding history establishes a basis for limited anticipatory compounding, not unlimited quantities. C is incorrect because quantity limits on anticipatory compounding apply independently of whether the product is commercially available.
- A pharmacist argues that because a patient called ahead to say she will pick up her compounded preparation later in the day, preparing the compound before the prescription arrives is patient-specific compounding rather than anticipatory compounding. Which of the following best evaluates this argument?
Answer: The argument is incorrect; patient-specific compounding requires a valid prescription, not just a phone call of intent.
Patient-specific compounding under 503A requires a valid prescription or medication order for an identified patient. A patient's phone call expressing intent to retrieve a prescription does not constitute a valid prescription. Compounding before receipt of a valid prescription remains anticipatory compounding subject to applicable limitations. A is incorrect because self-identification and expressed intent are not a valid prescription; the legal instrument is required. B is incorrect because known need does not satisfy the prescription requirement; the prescription itself is the trigger for patient-specific compounding. D is incorrect because prior prescriptions do not constitute a current valid prescription; the patient-specific designation requires a current, valid order.
- A patient with a documented allergy to a specific dye used in a commercially available tablet asks her pharmacist to compound the same drug in a dye-free formulation. The drug is commercially available only in the dye-containing form. Under Section 503A, which of the following best applies?
Answer: The pharmacy may compound this product if the prescriber confirms the dye-containing product is unsuitable for the patient due to a documented allergy.
Under Section 503A, a compounded drug that is essentially a copy of a commercially available product is permitted when the prescribing practitioner has determined that the commercially available product is not appropriate for the identified patient -- such as when a documented allergy makes the only available formulation clinically unsuitable. The prescriber's determination of inappropriateness is a required element of this exception, not merely an inference from clinical facts; it must be made by the practitioner and documented. A is incorrect because the commercially available exclusion has recognized exceptions when the prescribing practitioner determines the commercial product is inappropriate for the patient. B is incorrect because the shortage list is not the mechanism for this exception; the prescriber-determined clinical need exception is separate and does not require shortage status. C is incorrect because while the prescriber's determination is required, the statute does not mandate a specific format such as a formal written statement; what matters is that the practitioner's determination is made and documented.
- A physician asks a 503A compounding pharmacy to prepare a bulk supply of a hormone cream for his office to administer to multiple patients over the coming months without patient-specific prescriptions. Which of the following best describes whether the pharmacy may fulfill this request?
Answer: The pharmacy may not fulfill the request as 503A pharmacies require patient-specific prescriptions and cannot compound for office stock without 503B registration.
Section 503A is designed for patient-specific compounding. Preparing a bulk supply for a physician's office stock without patient-specific prescriptions is office-use compounding, which is generally a 503B activity. Some states permit limited office-use compounding under specific conditions, but large-scale office-use compounding without patient-specific prescriptions exceeds 503A's intended scope. B is incorrect because the physician being licensed does not authorize the 503A pharmacy to provide non-patient-specific bulk supply; the regulatory classification of the activity governs. C is incorrect because the controlled substance status of the compound is irrelevant to the patient-specific versus anticipatory compounding analysis. D is incorrect because a physician's signature does not change the regulatory classification of the activity.
- A 503B outsourcing facility received an FDA Form 483 observation during an inspection, noting that its sterility testing program did not meet cGMP requirements. Which of the following best analyzes the facility's obligations and appropriate response?
Answer: The facility must respond in writing with a corrective action plan to address the cGMP deficiencies noted in the Form 483.
An FDA Form 483 observation documents inspectional findings that may indicate violations of applicable requirements. For a 503B outsourcing facility required to comply with cGMP, a sterility testing deficiency is a significant finding requiring a timely written corrective action plan. Failure to respond adequately can escalate to a warning letter, injunction, or seizure. A is incorrect because Form 483 observations, while not themselves legally binding orders, are serious FDA communications that require timely response to avoid escalating enforcement action. C is incorrect because the FDA -- not the state board -- is the primary regulatory authority for 503B facilities and cGMP compliance. D is incorrect because a Form 483 observation does not automatically require facility shutdown; a corrective response and remediation are the expected steps.
- A 503A pharmacy is audited and found to have a pattern of compounding preparations essentially identical to FDA-approved commercially available products, with no documentation of patient-specific clinical need distinguishing the compounded from the commercial version. Which of the following best analyzes the compliance concern and appropriate response?
Answer: The pharmacy must document patient-specific need for compounded drugs to comply with FDCA Section 503A or stop compounding them.
Section 503A prohibits compounding essentially a copy of a commercially available product without a specific, documented patient need for a different formulation. A pattern of compounding commercial copies without clinical justification documentation raises a significant compliance concern. The pharmacy must either document the clinical necessity for each patient or stop compounding those products. A is incorrect because the presence of a prescription does not override the commercially available product exclusion; clinical justification is also required. B is incorrect because pricing is irrelevant to the regulatory analysis. C is incorrect because the do-not-compound list is an additional restriction but not the sole basis for the commercially available copy prohibition; Section 503A's language governs independently.
- During a severe drug shortage, a state governor issues an emergency order permitting all licensed pharmacies to compound and distribute the shortage drug without patient-specific prescriptions and without 503B registration. A 503A pharmacist is asked to begin large-scale compounding under this state order. Which of the following best analyzes the compliance implications?
Answer: The pharmacist should not proceed; federal FDCA requirements remain enforceable despite the state emergency order.
A state governor's emergency order can waive state pharmacy law requirements within the state's authority, but it cannot waive federal FDCA requirements. Large-scale compounding and distribution to multiple healthcare facilities without 503B registration remains a potential federal FDCA violation regardless of a state emergency order. The FDA may issue its own enforcement discretion guidance during recognized emergencies, but absent such federal action, the federal regulatory risk remains. A is incorrect because state emergency orders do not have authority to waive federal statutory requirements. B is incorrect because public health emergency status does not automatically override FDCA compounding restrictions; federal waivers must come from the FDA. D is incorrect because FDA enforcement discretion must come from the FDA itself and cannot be assumed based on a state declaration.
- During an FDA-recognized drug shortage, a 503A pharmacy begins compounding a drug that is normally commercially available but is currently unavailable. Which of the following best describes the applicable regulatory considerations?
Answer: A drug shortage allows compounding if 503A requirements are met, including patient-specific prescriptions, without permitting large-scale manufacturing or distribution.
During a recognized drug shortage, the FDA may exercise enforcement discretion regarding the commercially available product exclusion for 503A pharmacies, but the fundamental requirements of 503A remain in place. The pharmacy must still have patient-specific prescriptions, comply with compounding standards, and respect quantity limitations. The shortage does not convert 503A into a manufacturing license. B is incorrect because patient access concern does not override FDCA regulatory requirements; large-scale response requires 503B registration. C is incorrect because a shortage does not legally redefine a product's commercial availability status; FDA enforcement discretion is the applicable mechanism. D is incorrect because a drug shortage does not trigger DEA notification requirements; this is an FDA regulatory matter.
- A hospital pharmacy compounds a batch of 50 units of an IV antibiotic in anticipation of patient need on its infectious disease unit, based on typical weekly usage patterns. No patient-specific prescriptions have been received. Which of the following most accurately describes the hospital pharmacy's regulatory position?
Answer: Hospital pharmacies may compound limited quantities anticipatorily for in-system use under FDA enforcement discretion, not for large-scale distribution.
FDA's current enforcement discretion policy recognizes that hospital pharmacies may engage in very limited, in-system anticipatory compounding for their own patient population. This discretion is conditional -- FDA's guidance has generally tied it to in-system administration and use or discard within approximately 24 hours -- and does not constitute a formal 503A authorization or blanket permission for anticipatory production. A is incorrect because hospital pharmacies are not categorically exempt from anticipatory compounding requirements; FDA's enforcement discretion is conditional, not blanket. C is incorrect because formulary needs do not authorize unlimited anticipatory compounding; the enforcement discretion framework is limited and conditional on the described parameters. D is incorrect as an absolute statement; 503B registration is required for larger-scale compounding distributed to external facilities, but FDA's enforcement discretion may accommodate limited in-system anticipatory preparation within the applicable conditions.
- A 503B outsourcing facility wants to compound a drug product using a bulk drug substance that is not on the FDA-approved 503B bulk drug substances list. A hospital has expressed urgent clinical need and cannot identify a commercially available alternative. Which of the following best analyzes whether the outsourcing facility may compound this product?
Answer: The facility may compound the product if it is on the FDA drug shortage list or meets interim policy criteria for nominated substances.
Section 503B outsourcing facilities must generally use bulk drug substances on the FDA-approved 503B bulk list. However, FDA's current policy also recognizes additional pathways: facilities may compound from bulk substances used to produce a drug appearing on FDA's current drug shortage list, and FDA's interim policy permits compounding from certain Category 1 nominated substances -- those that have been nominated and that FDA has determined warrant evaluation -- while their final list determination is pending. B correctly identifies the general framework and these additional pathways. A is incorrect because a hospital's stated clinical need does not automatically qualify a substance for any pathway; the applicable FDA policies and lists govern. C is incorrect because clinical urgency alone is not a recognized exception; the shortage pathway requires the compounded drug to appear on FDA's current shortage list, not merely that an urgent clinical need exists. D is incorrect because state board notification does not substitute for FDA bulk list compliance or any of the recognized additional pathways.
- Which of the following best defines anticipatory compounding as distinguished from patient-specific compounding?
Answer: Anticipatory compounding involves preparing medications before receiving a prescription, based on expected demand, unlike patient-specific compounding, which requires an existing prescription for an individual.
Anticipatory compounding involves preparing a product before a specific patient's prescription has been received, based on a reasonable expectation of future need. Patient-specific compounding occurs after receipt of a prescription for an identified patient. Under FDCA Section 503A, anticipatory compounding must be based on prescription history and is limited in quantity, while 503B outsourcing facilities may compound anticipatorily without patient-specific prescriptions. A is incorrect because the distinction is not based on shortage status; it is based on whether a patient-specific prescription has been received. C is incorrect because both types of compounding may occur in various pharmacy settings subject to applicable regulations. D is incorrect because both types apply across all drug classes, not only controlled substances.
- A 503A compounding pharmacy has historically compounded approximately 20 units per month of a specific ophthalmic solution based on patient prescriptions. With no increase in prescriptions, the pharmacist compounds 200 units anticipatorily and distributes them to nearby ophthalmology clinics. Which of the following best describes the compliance concern?
Answer: The pharmacy compounded excess units without patient-specific prescriptions, violating 503A anticipatory compounding limits.
Under 503A, anticipatory compounding must be limited in quantity based on prescription history. Compounding 200 units when historical volume is 20 per month -- without patient-specific prescriptions -- goes well beyond permissible anticipatory limits and constitutes distribution to practitioners for office use, which is a 503B activity. A is incorrect because prior compounding history authorizes only limited and proportionate anticipatory compounding, not a tenfold increase. B is incorrect because the risk level of the product does not determine whether the quantity and distribution pattern are compliant. C is incorrect because local distribution to practitioners without patient-specific prescriptions still requires 503B registration; geographic proximity does not change the regulatory classification.
- A Section 503B outsourcing facility must comply with cGMP requirements. Which of the following best describes what this means compared to a 503A pharmacy's quality obligations?
Answer: cGMP mandates comprehensive quality systems and documentation, exceeding the USP standards followed by 503A pharmacies.
cGMP requirements applicable to 503B outsourcing facilities are more comprehensive than USP compounding standards followed by 503A pharmacies. cGMP includes systematic quality systems with in-process testing, environmental monitoring, equipment qualification, stability data, and detailed batch records. USP 795 and 797 standards for 503A pharmacies are rigorous but are less comprehensive than full pharmaceutical manufacturing-grade cGMP. A is incorrect because cGMP and USP compounding standards are substantively different in scope and rigor. C is incorrect because cGMP is more stringent, not more lenient, than USP compounding standards. D is incorrect because cGMP applies to all dosage forms at 503B facilities, not only sterile preparations.
- A 503A pharmacy's anticipatory compounding has grown over two years to the point where 80% of all compounding is anticipatory, 20% is patient-specific, and products are widely distributed to physician offices. Which of the following best analyzes the compliance concern?
Answer: The pharmacy's operations resemble manufacturing, requiring 503B registration due to high anticipatory compounding and distribution to practitioners.
The FDA has identified a high ratio of anticipatory to patient-specific compounding as a significant compliance concern under 503A. When 80% of compounding is anticipatory and products are distributed to physician offices rather than to individual patients with prescriptions, the pharmacy is effectively operating as a manufacturer or 503B facility without required registration and quality compliance. A correctly identifies the nature and significance of the problem. B is incorrect because state board compliance does not satisfy federal FDCA requirements; the two operate independently. C is incorrect because eventual patient dispensing does not retroactively convert manufacturing-scale activity into compliant 503A compounding. D is incorrect because the payment model is irrelevant to the regulatory classification of the compounding activity.
- A pharmacy that wants to function as a Section 503B outsourcing facility must fulfill which of the following requirements?
Answer: The pharmacy must register with the FDA, pay applicable fees, comply with cGMP requirements, and submit biannual reports to the FDA on the drugs it compounds.
Section 503B outsourcing facilities must register with the FDA annually, pay applicable user fees, comply with cGMP, and submit biannual reports to the FDA on the drug products they compound including names, strengths, and quantities. A is incorrect because DEA registration requirements for controlled substances are separate from 503B FDA registration; a DEA registration does not have to be obtained per state in every case. B is incorrect because 503B outsourcing facilities are not required to be co-located with any specific healthcare setting. D is incorrect because a state board certificate of need is not a federal FDA registration requirement; state licensure and federal registration are separate processes.
- A 503A pharmacy in State A ships a compounded preparation to a patient in State B pursuant to a valid patient-specific prescription. The same pharmacy also ships anticipatory preparations to physician offices in State B without patient-specific prescriptions. Which of the following analyzes the compliance difference between these two scenarios?
Answer: Shipping to patients with prescriptions may be allowed; shipping anticipatory preparations without prescriptions requires 503B registration.
The key distinction is the presence or absence of a patient-specific prescription. Shipping a compounded preparation to an individual patient pursuant to a valid prescription is patient-specific compounding and may be permissible under 503A with compliance with both states' laws. Shipping to physician offices without patient-specific prescriptions is office-use or large-scale anticipatory compounding, which is a 503B activity. A correctly identifies this distinction. B is incorrect because pharmacy licensing status in the shipping state does not resolve the federal regulatory classification issue. C is incorrect because crossing state lines does not automatically convert a legitimate 503A patient-specific activity into a 503B activity; the nature of the compounding is the determining factor. D is incorrect because interstate patient-specific compounding pursuant to valid prescriptions is an established and recognized practice.
